TIDMVRP 
 
 
   LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that all resolutions proposed at the 
Annual General Meeting held today were duly approved by shareholders by 
way of a poll. The 
https://www.globenewswire.com/Tracker?data=UZ7F2WI6AhjjP-g8XncEHkPGqQZKVHjl0OmoQDCw5GzvbJMAlkuH71ptZjp7I0QDsbreVWQlVhwd5ssfchksOWtf9cNKfR7rooTyyyDn-IyvAczeGRroBY4mJuCwKML9PbP8uVM7yXcqpYaikxYWyw== 
results of the poll are available on the Investors section of the 
Company's website, www.veronapharma.com. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. Verona Pharma is currently 
evaluating three formulations of ensifentrine for the treatment of COPD 
in Phase 2 clinical trials: nebulized, dry powder inhaler, and 
pressurized metered-dose inhaler. Ensifentrine also has potential 
applications in cystic fibrosis, asthma and other respiratory diseases. 
For more information, please visit www.veronapharma.com. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                             Tel: +44 (0)20 3283 4200 
--------------------------------------------  ------------------------- 
Victoria Stewart, Director of Communications  info@veronapharma.com 
--------------------------------------------  ------------------------- 
 
N+1 Singer                                    Tel: +44 (0)20 3283 4200 
--------------------------------------------  ------------------------- 
(Nominated Adviser and UK Broker) 
 Aubrey Powell / George Tzimas / Iqra 
 Amin (Corporate Finance) 
 Tom Salvesen (Corporate Broking) 
--------------------------------------------  ------------------------- 
 
Optimum Strategic Communications              Tel: +44 (0)20 3950 9144 
 (European Media and Investor Enquiries)       verona@optimumcomms.com 
--------------------------------------------  ------------------------- 
Mary Clark / Eva Haas / Hollie Vile 
--------------------------------------------  ------------------------- 
 
Argot Partners                                Tel: +1 212-600-1902 
 (US Investor Enquiries)                       verona@argotpartners.com 
--------------------------------------------  ------------------------- 
Stephanie Marks / Kimberly Minarovich / 
 Michael Barron 
--------------------------------------------  -------------------------

(END) Dow Jones Newswires

April 16, 2020 07:12 ET (11:12 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Verona Pharma Charts.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Verona Pharma Charts.